Lourdes Cucurull-Sanchez joins Pharmetheus as Scientific Lead for the Quantative Systems Pharmacology (QSP) platform

Lourdes brings extensive experience from several positions from large companies within drug development, and has made strong scientific contributions through her work within clinical pharmacology. The addition strengthens the company’s focus on QSP, ensuring continued innovation and latest expertise.

29.10.2024

Lourdes Cucurull-Sanchez is the current chair of the QSP Special Interest Group (SIG) at ISOP, International Society of Pharmacometrics.

– Bringing Lourdes onboard is an important step in putting further emphasis on developing our QSP capacity. Her experience will be of essence in meeting the growing demand for QSP services from our clients, says Marylore Chenel, Chief Research Officer and the recruiting manager.

The recruitment of a senior scientist within QSP, like Lourdes Cucurull-Sanchez, will allow the company to split their previous merged areas of PBPK/PBBM and QSP, into two separate focus areas.

Physiologically based biopharmaceutics (PBBM) is one of the company’s strengths, and with emerging guidance from FDA and EMA recognizing the use of PBPK within biopharmaceutics, formulation and drug product development, it will play a larger role in supporting Pharmetheus clients. Marylore Chenel explains:

– We believe there are more possibilities for clients to make use of PBPK/PBBM, and we aim to contribute to developing new methodology, tools and best practices. With Erik Sjögren, leading the PBPK/PBBM, and Lourdes Cucurull-Sanchez heading the QSP, Pharmetheus is armed to address the needs within both areas.

Dr. Marylore Chenel, Chief Research Officer, together with Dr. Niclas Jonsson, Scientific Director.

To me, Pharmetheus has always been a synonym for excellence, so I’m very proud of joining the team.

Before joining Pharmetheus, Lourdes Cucurull-Sanchez has worked at large companies like Pfizer and GSK, in positions within clinical pharmacology, and she is looking forward to applying her skills at Pharmetheus.

– To me, Pharmetheus has always been synonymous with excellence, so I’m very proud of joining the team. I look forward to developing the QSP services together with the R&D team, and helping our clients accelerate and de-risk their drug development programmes, says Lourdes Cucurull-Sanchez.

With this addition, Pharmetheus R&D has a team of four scientific leads: Dr. Martin Bergstrand, Model Informed Drug Development (MIDD), Dr. Niclas Jonsson, Pharmacometrics, Ass. Prof. Erik Sjögren, PBPK/PBBM and Dr. Lourdes Cucurull-Sanchez, QSP, securing broad scientific expertise to develop its consultants within pharmacometrics and MIDD, and to offer support and advice to clients, whether it involves study design, strategy or modeling and simulation.

Related content